Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration (FDA) licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok® influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.
"The approval of our Pearl River facility accelerates the growth of Protein Sciences and Flublok," said Manon Cox, President and CEO. "We will be able to manufacture Flublok at four times the scale compared to our Connecticut facility. This milestone enables us to substantially increase the availability of Flublok this year and in the future."
"Approval of the Pearl River facility has been our passion since we acquired the facility from Pfizer at the end of 2012," said Mireli Fino, Vice President of Manufacturing Operations. "It has been very rewarding to work with our dedicated Pearl River team that was able to manufacture the first batch of Flublok within 100 days and to now achieve FDA licensure. We look forward to the new opportunities licensure presents."
Deep learning techniques transform protein structure prediction